Jul. 2 at 3:21 PM
$ARCT announced a strategic collaboration with
$TMO to support the development of ARCT-032 for cystic fibrosis, leveraging Thermo Fisher’s integrated drug development platform spanning manufacturing, clinical research, and commercial readiness.
The partnership is designed to streamline the transition from late-stage clinical development into potential commercialization, with Thermo Fisher providing end-to-end operational support while Arcturus continues to lead the program.
From a market perspective, this type of collaboration is typically viewed as an execution and de-risking step, strengthening development infrastructure rather than changing the underlying clinical or regulatory thesis.
